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RESULTS: Two months after stroke informal caregivers
spent 22.7 hours a week (mean) on a range of different care
tasks. Six months after stroke they spent 25.1 hours a week
(mean) on the same tasks. Their mean EQ-5 score is 0.836
(n  195) after two months and 0.816 (n  138) after six
months. After two months 40 percent reports pain and
other complaints and 25 percent reports anxiety. Six
months after stroke this is respective 45 percent and 25 per-
cent. Health related quality of life results and time invested
will be compared to the general population by sex and age.
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Current cost-effectiveness models of antibiotic efficacy
typically do not consider the variability in relative inci-
dence of infectious agents or the probability of species-
specific antibiotic resistance. A model that incorporates
this variability in incidence and resistance will more accu-
rately represent epidemiological variances and associated
differences in treatment costs across patient populations.
OBJECTIVES: To create a model of antibiotic efficacy
that generates population-specific cost-effectiveness ra-
tios by including incidence and resistance rates of infec-
tious agents and can be adjusted to reflect epidemiologi-
cal data specific to different geographic regions.
METHODS: We constructed a decision tree model that
represents a user-defined infection (i.e. acute exacerba-
tion of chronic bronchitis). This model considers the rela-
tive incidence of infectious agents (bacterial and non-
bacterial/viral), the incidence of resistance among the
bacteria agents, and antibiotic efficacy against each infec-
tious agent and level of resistance. The model can repre-
sent “all-or-none” resistance such as that associated with
beta-lactamase production, or varying degrees of suscep-
tibility associated with other methods of resistance. The
model can represent clinical or in vitro efficacy, depend-
ing on the source of the data. In the event of insufficient
data to populate the resistance branch, this branch can be
collapsed out of the tree. The model will then represent
antibiotic efficacy for all infectious agents included.
RESULTS: The model generates cost-effectiveness ratios
identifying conditions where the antibiotic of interest is
cost effective or cost saving versus other antibiotics. Ra-
tios for individual infectious agents and levels of resis-
tance also identify specific populations where the antibi-
otic of interest has an advantage.
CONCLUSIONS: This model can incorporate geographic
diversity of and resistance in bacterial populations to gen-
erate cost-effectiveness ratios specific to different epidemi-
ological and geographic populations.
PMI19
COST-EFFECTIVENESS OF TUBERCULOSIS 
PREVENTIVE THERAPY IN HIV-INFECTED 
PATIENTS: STUDY OF MISSING VARIABLES
Chakrabarti A
Sikkim Manipal Institute of Medical Sciences, Gangtok, India
W
IT
HD
RA
W
N
